(Q36600306)

15 August 2017

1 reference

title

Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension (English)

1 reference

15 August 2017

Eoin O'Brien

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

15

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

1269-1277

1 reference

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

The role of angiotensin receptors in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Renin inhibition: new potential for an old therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Aldosterone in the development and progression of renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.10.1269

10.1517/13543784.15.10.1269

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference